Q1 EPS Estimates for Revolution Medicines Lifted by Wedbush

Revolution Medicines, Inc. (NASDAQ:RVMD) – Research analysts at Wedbush upped their Q1 2025 earnings per share estimates for Revolution Medicines in a research note issued on Wednesday, February 26th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.89) per share for the quarter, up from their prior estimate of ($0.90). Wedbush currently has a “Outperform” rating and a $67.00 target price on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.73) EPS, FY2026 earnings at ($3.96) EPS, FY2027 earnings at ($3.72) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at $2.90 EPS.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.11).

Other equities analysts have also issued reports about the stock. Stifel Nicolaus decreased their price objective on shares of Revolution Medicines from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Needham & Company LLC decreased their price target on Revolution Medicines from $60.00 to $59.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. UBS Group increased their price objective on Revolution Medicines from $65.00 to $71.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Guggenheim boosted their target price on Revolution Medicines from $82.00 to $87.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Revolution Medicines from $63.00 to $71.00 and gave the company an “overweight” rating in a report on Tuesday, December 3rd. Twelve analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $66.31.

Revolution Medicines Stock Performance

Shares of NASDAQ RVMD opened at $38.34 on Monday. The firm’s 50 day moving average price is $42.04 and its 200-day moving average price is $46.18. Revolution Medicines has a 52-week low of $29.00 and a 52-week high of $62.40. The company has a market cap of $6.45 billion, a PE ratio of -10.68 and a beta of 1.45.

Insider Buying and Selling

In related news, insider Mark A. Goldsmith sold 11,714 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $45.40, for a total value of $531,815.60. Following the transaction, the insider now directly owns 325,056 shares of the company’s stock, valued at approximately $14,757,542.40. This trade represents a 3.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thilo Schroeder purchased 1,304,347 shares of the business’s stock in a transaction on Thursday, December 5th. The shares were bought at an average cost of $46.00 per share, with a total value of $59,999,962.00. Following the acquisition, the director now directly owns 2,096,612 shares of the company’s stock, valued at $96,444,152. This trade represents a 164.64 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 18,678 shares of company stock valued at $847,981. 8.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc bought a new position in shares of Revolution Medicines in the fourth quarter worth approximately $34,000. Quarry LP purchased a new position in shares of Revolution Medicines during the 3rd quarter valued at $82,000. Sterling Capital Management LLC boosted its holdings in Revolution Medicines by 588.7% in the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock worth $86,000 after buying an additional 1,672 shares during the period. Farther Finance Advisors LLC increased its stake in Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock worth $90,000 after buying an additional 1,613 shares in the last quarter. Finally, Kapitalo Investimentos Ltda bought a new stake in Revolution Medicines during the fourth quarter valued at about $104,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.